PortfoliosLab logo
BioCardia, Inc. (BCDA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US09060U5074

CUSIP

09060U507

IPO Date

Mar 14, 2008

Highlights

Market Cap

$13.34M

EPS (TTM)

-$2.90

Total Revenue (TTM)

$3.00K

Gross Profit (TTM)

-$103.00K

EBITDA (TTM)

-$5.68M

Year Range

$1.63 - $6.15

Target Price

$15.50

Short %

3.31%

Short Ratio

1.12

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

BioCardia, Inc. (BCDA) returned 30.28% year-to-date (YTD) and -52.18% over the past 12 months. Over the past 10 years, BCDA returned -34.90% annually, underperforming the S&P 500 benchmark at 10.69%.


BCDA

YTD

30.28%

1M

43.80%

6M

23.48%

1Y

-52.18%

5Y*

-46.07%

10Y*

-34.90%

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of BCDA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202513.30%-18.62%26.37%23.62%-9.55%30.28%
2024-31.77%21.36%-26.00%-4.89%-20.43%-35.71%1.35%1.33%2.30%-25.32%-2.15%-4.39%-78.12%
202321.53%-13.39%-11.36%5.64%-14.08%50.85%-61.42%-24.27%-44.88%-13.40%66.85%6.92%-68.22%
2022-4.64%11.89%0.00%-25.60%9.09%-13.69%0.00%37.24%-2.51%0.52%-5.13%12.97%7.73%
202118.79%-5.60%11.86%-18.43%15.54%-2.93%-16.37%-11.14%6.44%-10.83%-26.79%-5.37%-43.93%
202027.72%-21.91%-7.63%40.12%-14.32%-41.03%4.17%-6.00%-3.40%-12.33%18.09%47.23%-5.98%
201910.00%7.58%-4.93%-8.89%-15.45%1.50%78.95%-71.00%-30.63%24.01%8.46%-20.00%-65.93%
201816.17%-18.32%-15.70%-25.53%3.57%-5.52%-2.92%-0.75%114.47%-10.63%-28.85%-33.33%-48.94%
2017-27.08%-17.47%-30.76%-11.80%-11.82%88.57%-13.64%-0.00%-18.42%-9.68%-20.63%-41.25%-81.87%
20160.00%-1.25%13.92%-13.33%76.28%10.55%-7.89%-0.43%-13.99%34.28%130.12%191.50%1,250.00%
20154.76%9.09%-16.67%0.00%6.00%-13.11%-2.28%-10.00%-4.63%-1.62%-10.53%17.65%-23.81%
20143.57%9.20%-9.47%-5.81%30.86%-0.00%3.77%27.18%-7.08%-15.38%-9.09%5.00%25.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BCDA is 29, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BCDA is 2929
Overall Rank
The Sharpe Ratio Rank of BCDA is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of BCDA is 3737
Sortino Ratio Rank
The Omega Ratio Rank of BCDA is 3737
Omega Ratio Rank
The Calmar Ratio Rank of BCDA is 1515
Calmar Ratio Rank
The Martin Ratio Rank of BCDA is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for BioCardia, Inc. (BCDA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

BioCardia, Inc. Sharpe ratios as of May 13, 2025 (values are recalculated daily):

  • 1-Year: -0.39
  • 5-Year: -0.36
  • 10-Year: -0.27
  • All Time: -0.19

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of BioCardia, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


BioCardia, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the BioCardia, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BioCardia, Inc. was 99.96%, occurring on Apr 21, 2025. The portfolio has not yet recovered.

The current BioCardia, Inc. drawdown is 99.94%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.96%Sep 12, 20083330Apr 21, 2025
-59.62%Mar 25, 200816May 22, 200837Sep 11, 200853

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BioCardia, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of BioCardia, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 71.3% positive surprise.


-1.20-1.00-0.80-0.60-0.40-0.200.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.25
-0.87
Actual
Estimate

Valuation

The Valuation section provides an overview of how BioCardia, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BCDA compared to other companies in the Biotechnology industry. BCDA currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BCDA relative to other companies in the Biotechnology industry. Currently, BCDA has a P/S ratio of 230.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BCDA in comparison with other companies in the Biotechnology industry. Currently, BCDA has a P/B value of 15.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items